Skip to content
Peptideworth

Provider review

New Wave Health review: it tells you who it is, and not what it charges

New Wave Health does the thing most of this market won't. It tells you who it is — a company name, a Virginia Beach street address, dated terms, and a postal address for opting out of arbitration. Then it runs a signup that asks for your name, email, phone, date of birth and home address across twenty-eight screens and never once shows you a price. The only number it publishes anywhere is "from $149/mo", hedged in its own words as confirmed after a provider reviews you. What is waiting at the end instead is a chart promising 18% of your body weight gone by week 24.

Publishes its company, its address and its terms — and still will not quote a price until it has your home address.

Worth trusting if

  • You want a company you can identify, write to and serve papers on, which this one publishes
  • You want the plain statement that compounded medicines are not FDA-approved, which it gives

Be skeptical if

  • You want to know what it costs before handing over your address, because the signup never says
  • You are planning around the 18%-by-week-24 chart, which no published trial supports
  • You want to know which pharmacy fills the prescription or which clinician writes it
Dispenses

Compounded only

Evidence

Phase 3 trials

Pharmacy

Not named

FDA letter

None found

By Grant Delaney, Research Editor

Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.

Visit New Wave Health

Opens mynewwavehealth.com. A link is not a recommendation to take anything.

Provenance

What New Wave Health actually dispenses

Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.

Compounded (503A)3 products

Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.

  • Compounded semaglutide injection
  • Compounded tirzepatide injection
  • GLP-1 Microdose

Evidence

Has the molecule been tested for what it is sold for?

One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.

Semaglutide · compounded
Phase 3 trials
Tirzepatide · compounded
Phase 3 trials
GLP-1 (molecule not named) · compounded
No trial for this use

2

Molecules with human evidence

For the use they are sold for, out of 3 products reviewed here. The evidence belongs to the molecule, not to New Wave Health.

3

Registry records cited

Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.

The comparison

What they claim, against what the trials show

Each claim below is quoted verbatim from New Wave Health’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.

Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim reaches past the trials
WHAT GLP-1 CARE CAN DO. A steady path to real, lasting results. TYPICAL GLP-1 PROGRESS −18% body weight. WEEK 0 · WEEK 12 · WEEK 24. In clinical trials, provider-supervised GLP-1 therapy produced consistent weight loss over time.

Read on the New Wave Health site, September 2026

Phase 3 trials

What the trials show for Semaglutide

  • NCT03548935 STEP 1Phase 3, completed, n=1,961. 68 weeks in 1,961 adults, titrated to semaglutide 2.4 mg. Reported a mean weight reduction of about 15% — at 68 weeks, not at 24.
  • NCT04184622 SURMOUNT-1Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg tirzepatide. Its roughly 20% mean is the highest published for an approved medicine in this class, and it took 72 weeks.

Eighteen percent of body weight by week 24, described as typical. STEP 1 reported about 15% after 68 weeks on semaglutide, so this promises more than the landmark trial produced in roughly a third of the time, and even SURMOUNT-1's tirzepatide result needed 72 weeks to reach about 20%. New Wave Health's own footnote calls the chart illustrative of published trial averages, which is where it fails: no published average has that shape. Two things compound it. The chart is on no public page — it appears only after a reader has given their name, email, phone, date of birth and home address — and the same screen still shows no price.1,2

Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim matches the trials
Tirzepatide — Advanced Weight Loss. Provider-guided GLP-1 care, delivered to your door.

Read on the New Wave Health site, September 2026

Phase 3 trials

What the trials show for Tirzepatide

  • NCT04184622 SURMOUNT-1Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly, mean reduction of roughly 20% at the top dose.

The public tirzepatide page promises nothing measurable, so there is nothing on it to weigh against SURMOUNT-1. The restraint ends at the signup: the same 18%-by-week-24 chart closes the tirzepatide route as it does the semaglutide one, with no distinction drawn between two molecules whose trials ran to different lengths and different results. Someone who chose tirzepatide is shown the semaglutide promise.2

GLP-1 MicrodoseGLP-1 (molecule not named) · Compounded (503A)No trial supports this claim
GLP-1 Microdose — lower-dose GLP-1.

Read on the New Wave Health site, September 2026

No trial for this use

No trial can be matched to this product because New Wave Health never says what is in it. Searched on September 13, 2026 across every page of its own site — the homepage, all three treatment pages, the terms and the privacy notice — and across all twenty-eight screens of the signup: no molecule and no dose is named for the microdose product anywhere. A trial record cannot be attached to an unnamed drug, and guessing which one it is would be inventing the evidence base.

A product described by its dose relative to an unnamed drug. Even with the molecule named it would sit outside the published evidence: STEP 1 and SURMOUNT-1 both titrated participants up to a maintenance dose and measured them there, so a deliberately reduced dose is a different treatment rather than a cheaper share of the same one. Unnamed, there is nothing to weigh at all.

Dispensing chain

Who actually fills your prescription

Pharmacy not named
Read the full account

No pharmacy is named, and no clinician either. The footer describes the arrangement as a category — a concierge telehealth platform that facilitates access to independent, US board-certified clinical providers and state-licensed compounding pharmacies — and names neither, on their site or across the whole signup. Nothing says whether the medication is made to order under a prescription or dispensed ready-made. The same disclaimer does say, plainly, that compounded medications are not FDA-approved and that their safety, efficacy and quality have not been independently verified by the FDA. Against the rest of this market that sentence is good; against this company's own corporate disclosure, which is unusually complete, the silence about the supply chain stands out.

Read on the New Wave Health site, September 2026.

Quality

Third-party testing, and what is published

Describes a testing regime

Nothing published on the pages searched

Certificate of analysis readable

No lot report a buyer can open

Read the full testing account

No certificate of analysis, potency, purity or sterility result appears anywhere on the site or in the signup. The trust signals are social and undated — a member count, an average care rating shown as a bare figure, before-and-after photographs marked "individual results vary", and a testimonial screen inserted partway through the intake. The only quantified clinical claim on the property is the 18%-by-week-24 chart, and it is visible only to people who have already completed the intake.

Read on the New Wave Health site, September 2026.

Licensing

Licensed to dispense, and where

Coverage

New Wave Health publishes no list of states and makes no fifty-state claim, checked on September 13, 2026 across the homepage, the three treatment pages, the terms and the full signup. The signup never asks which state you are in; it asks for a full shipping address instead, at screen twenty-five.

Read the full licensing claim

The company is named and located: New Wave Health LLC, at 1832 Kempsville Road Suite 112, Virginia Beach, Virginia 23464, in terms last updated June 1, 2026 — with the same address given again for opting out of arbitration. That is more corporate disclosure than either of the two brands sharing this template. No clinician is named anywhere, and the published contact is a named individual's mailbox rather than a support desk.

Read on the New Wave Health site, September 2026.

Regulatory

The FDA warning letter

Checked, and none found

A search of the 113 warning letters issued to telehealth firms in the September 9, 2025, February 20, 2026 and June 8, 2026 enforcement waves — matched on full company name rather than substring, because a substring match attaches one company’s regulatory history to another — returns no entry for New Wave Health (New Wave Health LLC). That is a statement about those three waves as of September 2026, not a claim that no action exists anywhere.

We did this ourselves

What happens when you sign up with New Wave Health

We went through New Wave Health’s signup ourselves in September 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.

  1. What would you like support with
  2. How active are you usually
  3. How much sleep do you normally get
  4. How often are you stressed
  5. What is your gender
  6. Height, current weight and goal weight
  7. A BMI analysis screen, with a score, an "elevated" label and a "success outlook" of 92%
  8. First name and last name
  9. Email address
  10. Phone number
  11. Which best describes your body shape
  12. What is your ethnicity
  13. A symptom checklist
  14. A diagnosis checklist, including thyroid cancer and endocrine neoplasia
  15. Have you had any surgeries or procedures
  16. Have you had any weight-loss surgeries
  17. A testimonial screen with a before-and-after photograph
  18. Have you ever taken a GLP-1 medication
  19. Do you take any medications or supplements
  20. Are you allergic to any of these
  21. Any other medication or food allergies
  22. What is your resting heart rate
  23. How disruptive would side effects be to your routine
  24. Your date of birth
  25. Your full shipping address
  26. A final consent screen, with a chart promising 18% of body weight lost by week 24
No price until you finish the questions
  • No price appears at any point in the signup — not on one of the twenty-eight screens we cleared on September 13, 2026.
  • The only figure published anywhere is "from $149/mo", which New Wave Health itself qualifies as confirmed after a provider reviews you.
  • Your email is collected at screen nine, before any question about medication, allergies or diagnosis.
  • Your date of birth and full shipping address are both requested before any price is shown.
  • A success figure of 92% appears twice — once on the BMI screen and once on the screen headed medical review — before a clinician has seen anything.
  • The 18%-by-week-24 chart appears only on the final screen, invisible to anyone comparing providers from outside.
  • The published contact is a named person's mailbox rather than a support address, and it doubles as the arbitration opt-out address.
  • The final screen requires confirming your answers are true, accurate and complete before the qualification button unlocks — where we stopped, because ours were not.

New Wave Health support

Assessment

What holds up, and what does not

What holds up
  • It names the company and its street address, in its terms and again in the footer.
  • Its terms are dated, and give a postal address for opting out of arbitration.
  • Its disclaimer says plainly that compounded medications are not FDA-approved and unverified by the FDA.
Show 4 more
  • A published telephone number as well as an email address.
  • Its public treatment pages make no outcome claim at all.
  • The final screen's chart carries a hedge — illustrative, individual results vary.
  • No FDA warning letter.
What does not
  • No price appears on any of the twenty-eight signup screens, or anywhere else on the site.
  • It asks for your date of birth and full shipping address before showing you a number.
  • Your email is collected at screen nine, before a single clinical question.
Show 7 more
  • Its chart promises 18% of body weight lost by week 24, beating the landmark trial in a third of the time.
  • That chart is visible only after the intake, so nobody comparing providers from outside can see it.
  • A 92% success figure appears twice before any clinician has looked at anything.
  • The same chart closes both the semaglutide and the tirzepatide routes, though the trials differ.
  • Its microdose product names no molecule and no dose anywhere.
  • No pharmacy is named, and nothing says whether the medication is made to order.
  • No clinician is named, and the published contact is a personal mailbox rather than a support desk.

Verdict

The bottom line

Give this company credit for the part most of its rivals skip. You can find out who it is, where it is, and how to take it to arbitration. Then judge what it does with your details: twenty-eight screens, your date of birth and your home address, and still no price. The chart at the end promises more than the landmark trial delivered. Ask for a figure in writing first.

Visit New Wave Health

Opens mynewwavehealth.com. A link is not a recommendation to take anything.

It tells you who it is

Most of this market won't. New Wave Health does, in its Terms of Use, last updated 1 June 2026:

"New Wave Health LLC … owns and operates the website located at mynewwavehealth.com"

With an address — 1832 Kempsville Road Suite 112, Virginia Beach, VA 23464 — in the footer, in the terms, and again as the address you'd write to if you wanted to opt out of arbitration.

That last detail matters. A company that tells you where to send an arbitration opt-out is a company you can actually reach.

Worth noting against its two lookalikes: rxbella.com publishes no company at all, and evioramd.com publishes one only in a browser tab. Same template, three very different levels of disclosure.

Full analysis — 4 more sectionsAnd not what it charges · What is waiting at the end · Two screens earlier · The same twenty-eight screens, twice more

And not what it charges

The only figure anywhere on the site:

"Plans from $149/mo · confirmed after provider review"

So on 13 September 2026 we completed the signup to find the real one. Twenty-eight screens — goals, activity, sleep, stress, sex, height, weight, goal weight, a BMI analysis, name, email, phone, body shape, ethnicity, symptoms, diagnoses, surgeries, GLP-1 history, medications, allergies, resting heart rate, side-effect tolerance, date of birth, and a full shipping address.

No dollar figure at any step.

What is waiting at the end

The final screen, headed "WHAT GLP-1 CARE CAN DO":

TYPICAL GLP-1 PROGRESS

−18% body weight

WEEK 0 · WEEK 12 · WEEK 24

STEP 1 reported about 15% — after 68 weeks. 1 SURMOUNT-1's tirzepatide result reached roughly 20% — after 72 weeks. 2

18% by week 24 promises more than the landmark semaglutide trial delivered, in about a third of the time. The footnote calls it "illustrative of published trial averages". No published average looks like that.

And it's on no public page. Only people who have already handed over their contact details and home address ever see it.

Two screens earlier

The BMI screen shows "Your success outlook 92%". The screen headed "Your Medical Review" shows "Success Probability 92%" and "You could reach your goal weight in about 31 weeks."

No clinician has looked at anything at that point. Those numbers come from height, weight and a goal.

The same twenty-eight screens, twice more

rxbella.com and evioramd.com run the identical intake — we walked Eviora MD's the same day and got the same twenty-eight screens in the same order, ending on the same −18% panel word for word.

None of that establishes a relationship between the three, and only New Wave Health publishes a company at all, so there's nothing to compare the other two against. It matters for one practical reason: if you're weighing two of these against each other, you may be weighing the same product twice.

Questions

Frequently asked questions

What does New Wave Health cost?

It publishes "from $149/mo" and qualifies that itself as confirmed after a provider reviews you. We completed twenty-eight signup screens on September 13, 2026 — including date of birth and full shipping address — and were shown no figure at any point.

Is 18% of body weight by week 24 realistic?

Not on the published record. STEP 1 reported about 15% after 68 weeks of semaglutide, and SURMOUNT-1's tirzepatide result reached roughly 20% after 72 weeks. A chart promising 18% at week 24 claims more than the landmark trial achieved in around a third of the time.

Who is New Wave Health?

New Wave Health LLC, at 1832 Kempsville Road Suite 112 in Virginia Beach, Virginia, named in terms dated June 1, 2026. It's the most complete corporate disclosure of the three brands running this template, and it's a genuine point in the company's favor.

What is the 92% success probability?

A figure the site generates from your height, weight and goal weight, shown on two screens before any clinician has seen anything. No trial reports a success probability for an individual — published results are averages with a spread around them, including people who didn't respond.

Who makes the medication?

New Wave Health doesn't say. Its disclaimer describes state-licensed compounding pharmacies as a category and names none, and nothing says whether your medication is made to order under a prescription or dispensed ready-made. No clinician is named either.

Glossary

Key terms

Show definitions
STEP 1
The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021.
SURMOUNT-1
The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg, published in the New England Journal of Medicine in 2022.
Compounded
Made to order by a pharmacy for an individual patient rather than manufactured and approved as a finished product. Compounded drugs are not FDA-approved and the FDA has not evaluated their safety, effectiveness or quality.

Compare

Others selling what New Wave Health sells

Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.

Method

How we checked this

Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.

Read our methodology

Claims read first-party

Every quoted claim was read off New Wave Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.

Trials read from the registry

Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.

Absence claims bounded

Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.

Letters matched on full name

FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.

Sources

References

Show all 2 sources
  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults, mean weight reduction of about 15% reported at 68 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults, roughly 20% mean reduction at the top dose reported at 72 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.